Intravitreal Triamcinolone Acetonide for the Treatment of Immune Recovery Uveitis Macular Edema

Ophthalmology

Volumn 114, Issue 2, 2007, Pages 334-339

  Morrison, Victoria L ^a   Kozak, Igor ^a   LaBree, Laurie D ^b   Azen, Stanley P ^b   Kayicioglu, Ozcan O ^a   Freeman, William R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; TRIAMCINOLONE ACETONIDE; VALGANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RECOVERY UVEITIS; INTERVENTION STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA EDEMA; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; UVEITIS; VIRUS REACTIVATION; VISUAL ACUITY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS RETINITIS; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MACULAR EDEMA, CYSTOID; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TRIAMCINOLONE ACETONIDE; UVEITIS; VISUAL ACUITY; VITREOUS BODY;

EID: 33846535809     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2006.07.013     Document Type: Article

References (37)

1. Song M.K., Karavellas M.P., MacDonald J.C., et al. Characterization of reactivation of cytomegalovirus retinitis in patients healed after treatment with highly active antiretroviral therapy. Retina 20 (2000) 151-155
2. Autran B., Carcelain G., Li T.S., et al. Positive effects of combined antiretroviral therapy on CD4 T cell homeostasis and function in advanced HIV disease. Science 277 (1997) 112-116
3. Lederman M.M., Connick E., Landay A., et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 178 (1998) 70-79
4. Markowitz M., Saag M., Powderly W.G., et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. New Engl J Med 333 (1995) 1534-1539
5. Karavellas M.P., Lowder C.Y., Macdonald J.C., et al. Immune recovery vitreitis associated with inactive cytomegalovirus retinitis. Arch Ophthalmol 116 (1998) 169-175
6. Karavellas M.P., Plummer D.J., Macdonald J.C., et al. Incidence of immune recovery vitreitis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 179 (1999) 697-700
7. Karavellas M.P., Song M., Macdonald J.C., and Freeman W.R. Long-term posterior and anterior segment complications of immune recovery uveitis associated with cytomegalovirus retinitis. Am J Ophthalmol 130 (2000) 57-64
8. Canzano J.C., Reed J.B., Morse L.S., et al. Vitreomacular traction syndrome following highly active antiretroviral therapy in AIDS patients with cytomegalovirus retinitis. Retina 18 (1998) 443-447
9. Whitcup S.M. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. JAMA 283 (2000) 653-657
10. Robinson M.R., Reed G., and Csaky K.G. Immune-recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy. Am J Ophthalmol 130 (2000) 49-56
11. Nguyen Q.D., Kempen J.H., Bolton S.G., et al. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol 129 (2000) 634-639
12. Jabs D.A., Van Natta M.L., and Kempen J.H. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 133 (2002) 48-61
13. Dunn J.P. Immune recovery uveitis. Hopkins HIV Report (2001) 9-10
14. Holland G.N. Immune recovery uveitis. Ocul Immunol Inflamm 7 (1999) 215-221
15. El-Bradey M.H., Cheng L., Song M.Y., et al. Long-term results of treatment of macular complications in eyes with immune recovery uveitis using a graded treatment approach. Retina 24 (2004) 376-382
16. Karavellas M.P., Azen S.P., and MacDonald J.C. Immune recovery vitritis and uveitis in AIDS. Clinical predictors, sequelae, and treatment. Retina 21 (2001) 1-9
17. Kosobucki B.R., Goldberg D.E., Bessho K., et al. Valganciclovir therapy for immune recovery uveitis complicated by macular edema. Am J Ophthalmol 137 (2004) 636-638
18. Henderson H.W., and Mitchell S.M. Treatment of immune recovery vitreitis with local steroids. Br J Ophthalmol 83 (1999) 540-545
19. Jonas J.B., Kreissig I., Söfker A., and Degenring R.F. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 121 (2003) 57-61
20. Jonas J.B., and Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 132 (2001) 425-427
21. Benhamou N., Massin P., Haouchine B., et al. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol 135 (2003) 246-249
22. Jonas J.B., Kreissig I., and Degenring R.F. Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol 136 (2003) 384-386
23. Antcliff R.J., Spalton D.J., Stanford M.R., et al. Intravitreal triamcinolone for uveitis cystoid macular edema: an optical coherence tomography study. Ophthalmology 108 (2001) 765-772
24. Degenring R.F., and Jonas J.B. Intravitreal injection of triamcinolone acetonide as treatment for chronic uveitis. Br J Ophthalmol 87 (2003) 361
25. Park C.H., Jaffe G.J., and Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 136 (2003) 419-425
26. Greenberg P.B., Martidis A., Rogers A.H., et al. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 86 (2002) 247-248
27. Scott I.U., Flynn H.W., and Rosenfeld P.J. Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema. Am J Ophthalmol 136 (2003) 737-739
28. Kosobucki BR, Freeman WR, Cheng L. Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomized eye. Br J Ophthalmol 2006;90:705-8.
29. Arevalo J.F., Munguia D., Faber D., et al. Correlation between intraocular pressure and CD4+ T-lymphocyte counts in patients with human immunodeficiency virus with and without cytomegalovirus retinitis. Am J Ophthalmol 122 (1996) 91-96
30. Jonas J.B., Kreissig I., Söfker A., et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 121 (2003) 57-61
31. Morrison VL, Koh HJ, Cheng L, et al. Intravitreal toxicity of the Kenalog vehicle (benzyl alcohol) in rabbits. Retina 2006;26:339-44.
32. Jonas J.B., Kreissig I., and Degenring R. Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 240 (2002) 873-874
33. Jonas J.B., Hayler J.K., Söfker A., and Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 131 (2001) 468-471
34. Rodriguez-Coleman H., Yuan P., Kim H., et al. Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol 122 (2004) 1085-1086
35. Jonas J.B., Degenring R.F., and Kreissig I. Intravitreal injection of triamcinolone for diffuse macular edema. Authors Reply. Arch Ophthalmol 122 (2004) 1086-1088
36. Garcia-Arumi J., Boixadera A., Giralt J., et al. Comparison of different techniques for purification of triamcinolone acetonide suspension for intravitreal use. Br J Ophthalmol 89 (2005) 1112-1114
37. Dalessandro L., and Bottaro E. Reactivation of CMV retinitis after treatment with subtenon corticosteroids for immune recovery uveitis in a patient with AIDS. Scand J Infect Dis 34 (2002) 780-782